Skip to main content
. 2019 Mar 1;3(3):269–275. doi: 10.1002/ags3.12243

Figure 1.

Figure 1

JCOG1109 study design. Patients with locally advanced esophageal cancer were randomized to any of the three arms consisting of arm A (preoperative CF), arm B (preoperative DCF), and arm C (preoperative CF‐RT), followed by surgery. Primary endpoint was overall survival. CF, cisplatin plus 5‐fluorouracil (5‐FU); CF‐RT, radiotherapy with CF; DCF, docetaxel, cisplatin plus 5‐FU; JCOG, Japan Clinical Oncology Group